
    
      This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period
      crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to
      moderate AD.

      16 participants (8 randomized to 300 mg CT1812, 8 randomly assigned to placebo during each
      treatment period): the 8 participants randomly assigned to CT1812 in Treatment Period 1 will
      receive placebo in Treatment Period 2; the 8 participants randomly assigned to placebo in
      Treatment Period 1 will receive CT1812 in Treatment Period 2.
    
  